Next Article in Journal
Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer
Next Article in Special Issue
Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer
Previous Article in Journal
Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors
Previous Article in Special Issue
Hybrid 18F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study
Brief Report

99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma

LRB, CHU Grenoble Alpes, INSERM U1039, Université Grenoble Alpes, 38000 Grenoble, France
Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco
IGDR (Institut de génétique et développement de Rennes), UMR CNRS 6290, Université de Rennes, 35000 Rennes, France
Institute for Research on Cancer and Aging of Nice, Centre Antoine Lacassagne, CNRS UMR 7284, INSERM U1081, Université Côte d’Azur, 06200 Nice, France
Author to whom correspondence should be addressed.
Cancers 2019, 11(10), 1531;
Received: 20 September 2019 / Revised: 8 October 2019 / Accepted: 8 October 2019 / Published: 10 October 2019
(This article belongs to the Special Issue Role of Medical Imaging in Cancers)
Mesothelin is a membrane-associated protein overexpressed in pancreatic ductal adenocarcinoma (PDAC). Some mesothelin-targeted therapies are in clinical development but the identification of patients eligible for such therapies is still challenging. The objective of this study was to perform the imaging of mesothelin in mice models of PDAC with a technetium-labeled anti-mesothelin single-domain antibody (99mTc-A1). Methods: The Cancer Genomic Atlas (TCGA) database was used to determine the prognostic role of mesothelin in PDAC. 99mTc-A1 was evaluated both in vitro in PDAC cells (SW1990 and AsPC-1) and in vivo in an experimental model of mesothelin-expressing PDAC (AsPC-1) in mice. Results: TCGA analysis showed that PDAC patients with high mesothelin expression had a shorter overall survival (P = 0.00066). The binding of 99mTc-A1 was 2.1-fold greater in high-mesothelin-expressing AsPC-1 cells when compared to moderate-mesothelin-expressing SW1990 cells (p < 0.05). In vivo, the 99mTc-A1 uptake was 3.5-fold higher in AsPC-1-derived tumors as compared to a technetium-labeled irrelevant antibody (99mTc-Ctl) (p < 0.01). Conclusions: 99mTc-A1 accurately allows imaging of mesothelin-expressing experimental PDAC tumors. Our experiments paved the way for the development of a companion test for mesothelin-targeted therapies. View Full-Text
Keywords: PDAC; Mesothelin; noninvasive imaging PDAC; Mesothelin; noninvasive imaging
Show Figures

Figure 1

MDPI and ACS Style

Montemagno, C.; Cassim, S.; Trichanh, D.; Savary, C.; Pouyssegur, J.; Pagès, G.; Fagret, D.; Broisat, A.; Ghezzi, C. 99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma. Cancers 2019, 11, 1531.

AMA Style

Montemagno C, Cassim S, Trichanh D, Savary C, Pouyssegur J, Pagès G, Fagret D, Broisat A, Ghezzi C. 99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma. Cancers. 2019; 11(10):1531.

Chicago/Turabian Style

Montemagno, Christopher, Shamir Cassim, Dimitry Trichanh, Clara Savary, Jacques Pouyssegur, Gilles Pagès, Daniel Fagret, Alexis Broisat, and Catherine Ghezzi. 2019. "99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma" Cancers 11, no. 10: 1531.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop